Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020

Dupilumab is the only biologic therapy currently approved in Europe and the United States for severe atopic dermatitis in patients 6 years of age or older. Off-label use is rationalized in younger children with severe atopic dermatitis. Decisions about vaccination for children on dupilumab are compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Cabriales, Sylvia A., Kirchhof, Mark G., Constantinescu, Cora M., Murguia-Favela, Luis, Ramien, Michele L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169786/
https://www.ncbi.nlm.nih.gov/pubmed/34076879
http://dx.doi.org/10.1007/s40257-021-00607-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169786/
https://www.ncbi.nlm.nih.gov/pubmed/34076879
http://dx.doi.org/10.1007/s40257-021-00607-6

Ejemplares similares